2022-RA-1094-ESGO Implementation of a tri-modal prehabilitation intervention – KORE-INNOVATION: the first prospective clinical trial to assess a perioperative pathway to reduce postoperative complications in ovarian cancer patients

Abstract

IQR) of -160 (-297; 35.2) in the total cohort, -272 (-376; -122) in arm A, 105 (-109; 221) in arm B and -160 (-663; -109) in arm C, p=0.008. High chitinase response was associated with high CA-125 ELIMination rate constant K (KELIM), a marker of chemosensitivity (Fisher exact test, p=0.042). Conclusion Chitinase activity should not be considered, in the context of ovarian cancer as an aging biomarker, but chitinase response appears as a promising marker of chemosensitivity.